Tableau to Present at Upcoming Investor Conferences
Get Alerts DATA Hot Sheet
Join SI Premium – FREE
SEATTLE, Feb. 21, 2017 /PRNewswire/ -- Tableau (NYSE: DATA), a global leader in visual analytics, today announced that Francois Ajenstat, Chief Product Officer, will be presenting at the following upcoming investor conferences:
- Pacific Crest's 12th Annual Emerging Technology Summit on Tuesday, February 28, 2017 at 11:30am PT at The Park Central Hotel in San Francisco, CA;
- The JMP Securities Technology Conference on Tuesday, February 28, 2017 at 3:30pm PT at the Ritz Carlton in San Francisco, CA; and
- The Morgan Stanley Technology, Media & Telecom Conference on Wednesday, March 1, 2016 at 4:00pm PT at The Palace Hotel in San Francisco, CA.
Live webcasts, as well as a replays, will be available on the Company's investor relations website at: http://investors.tableau.com/overview/default.aspx.
About Tableau
Tableau (NYSE: DATA) helps people see and understand data. Tableau helps anyone quickly analyze, visualize and share information. More than 54,000 customer accounts get rapid results with Tableau in the office and on-the-go. Over 300,000 people use Tableau Public to share public data in their blogs and websites. See how Tableau can help you by downloading the free trial at www.tableau.com/trial.
Tableau and Tableau Software are trademarks of Tableau Software, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tableau-to-present-at-upcoming-investor-conferences-300409295.html
SOURCE Tableau
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nord Precious Metals Further Extends Castle East Robinson Zone with 13,620 g/t Silver and 1.84% Cobalt over 0.6m, Including 25,803 g/t Silver (752.7 oz/ton) and 3.60% Cobalt over 0.30m
- Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
- VOKA 3D Anatomy & Pathology Expands Free Access to the Entire 3D Model Library
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Morgan Stanley, JMP Securities, Pacific Crest SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share